151751-Najiba-Chargi

232 CHAPTER 12 REFERENCES 1. Bonomo P, Loi M, Desideri I, et al. Incidence of skin toxicity in squamous cell carcino- ma of the head and neck treated with ra- diotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol . 2017;120:98- 110. doi:10.1016/j.critrevonc.2017.10.011 2. Machtay M, Moughan J, Trotti A, et al. Fac - tors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol . 2008;26(21):3582- 3589. doi:10.1200/JCO.2007.14.8841 3. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. 2017. doi:10.1016/j.oraloncol - ogy.2017.05.012 4. Hirasawa K, Okamoto I, Motohashi R, et al. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients. Auris Nasus Larynx . 2017;44(6):724-728. doi:10.1016/j. anl.2017.01.005 5. Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cispla- tin and radiotherapy for locally advanced head and neck cancer: A randomized phase II trial. J Clin Oncol . 2016;34(5):427-435. doi:10.1200/JCO.2015.63.1671 6. Swartz JE, Pothen AJ, Wegner I, et al. Feasibility of using head and neck CT im - aging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol . 2016;62:28-33. doi:10.1016/j.oraloncolo - gy.2016.09.006 7. Bril SI, Wendrich AW, Swartz JE, et al. In - terobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra. Eur Arch Oto-Rhino-Laryngology . 2019;276(4):1175-1182. doi:10.1007/s00405- 019-05307-w 8. Chargi N, Ansari E, Huiskamp LFJ, Bol G, de Bree R. Agreement between skeletal muscle mass measurements using computed to- mography imaging andmagnetic resonance imaging in head and neck cancer patients. Oral Oncol . 2019;99:104341. doi:10.1016/j. oraloncology.2019.06.022 9. Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemother- apy toxicity and time to tumor progression inmetastatic breast cancer patients receiv- ing capecitabine treatment. Clin Cancer Res . 2009;15(8):2920-2926. doi:10.1158/1078- 0432.CCR-08-2242 10. Barret M, Antoun S, Dalban C, et al. Sarco - penia is linked to treatment toxicity in pa- tients with metastatic colorectal cancer. Nutr Cancer . 2014;66(4):583-589. doi:10.10 80/01635581.2014.894103 11. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting tox- icities in renal cancer patients. Br J Cancer . 2013;108(5):1034-1041. doi:10.1038/ bjc.2013.58 12. Go S Il, Park MJ, Song HN, et al. Sarcopenia and inflammation are independent pre- dictors of survival in male patients newly diagnosed with small cell lung cancer. Sup- port Care Cancer . 2016;24(5):2075-2084. doi:10.1007/s00520-015-2997-x 13. Tan BHL, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant che- motherapy for oesophago-gastric cancer. Eur J Surg Oncol . 2015;41(3):333-338. doi:10.1016/j.ejso.2014.11.040 14. B. Heymsfield S, Wang Z, Baumgartner RN, Ross R. Human Body Composition: Advanc - es in Models and Methods. Annu Rev Nutr . 1997;17(1):527-558. doi:10.1146/annurev. nutr.17.1.527